ClinicalTrials.gg
CompletedNCT02686138T3MPO-2Updated Apr 22, 2020Results posted

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C

A Phase 3 interventional study of Tenapanor and Placebo in Constipation Predominant Irritable Bowel Syndrome, sponsored by Ardelyx. Completed at 117 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-04-22.

Sponsored by Ardelyx · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
593
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing tenapanor in Constipation — 3 open to participants now, 4 under way, 3 of them phase 3. tenapanor · Constipation.

Enrollment
3rd of 11
593 · median 186
Started
2015
with 1 other
Phase 3
7 of 11
2 open now
Registered
4th of 11
by date
Lead sponsor
9 of 11
Ardelyx

Among the 11 studies testing tenapanor in Constipation, this one is the 3rd largest by enrollment, is one of 2 that started in 2015, is one of 7 in phase 3, and was the 4th registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

3 of the 11 studies testing tenapanor in Constipation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About tenapanor

tenapanor: first FDA approval 2019 (IBSRELA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing tenapanor in Constipation, or all of them as a file.
02

Study summary

This phase 3, 26-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of one dose of Tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as defined by the ROME III criteria and who have active disease as determined after a two-week screening period. Subjects who qualify and are randomized into the study will either receive 50mg BID of Tenapanor (1:1) for a 26 week treatment period.

Read the detailed description

During the 26-week double-blind treatment period, subjects will record daily assessments including: frequency and timing of bowel movements; sensation of complete bowel emptying; consistency of bowel movements; degree of straining, worst abdominal pain, abdominal discomfort, abdominal bloating, abdominal fullness and abdominal cramping; and use and timing of rescue medication. Subjects will also record weekly assessments including: adequate relief of IBS symptoms, degree of relief of IBS symptoms, IBS severity, and constipation severity.

03

Conditions studied

  • Constipation Predominant Irritable Bowel Syndrome
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged 18 to 75 years, inclusive
  • Females must be of non-; If of child-bearing potential, must have negative pregnancy test and confirm the use of one of the appropriate means of
  • Males must agree to use appropriate methods of barrier contraception or have documented surgical sterilization
  • Subject meets definition of IBS-C using Rome III Criteria for the Diagnosis of IBS
  • A colonoscopy based on AGA guidelines; every 10 years at ≥50 years old

Exclusion criteria

Exclusion Criteria:

  • Functional diarrhea as defined by Rome III criteria
  • IBS with diarrhea (IBS-D), mixed IBS (IBS-M), or unsubtyped IBS as defined by Rome III criteria
  • Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the GI tract within 6 months prior to screening, or active disease within 6 months prior to screening; including but not limited to cancer, inflammatory bowel disease, diverticulitis, duodenal ulcer, erosive esophagitis, gastric ulcer, pancreatitis (within 12 months of screening), cholelithiasis, amyloidosis, ileus, non-controlled GERD, gastrointestinal obstruction or carcinoid syndrome.
  • Potential CNS cause of constipation (e.g., Parkinson's disease, spinal cord injury, or multiple sclerosis)
  • Subject has a history or current evidence of laxative abuse (in the clinical judgment of physician)
  • Hepatic dysfunction ( [SGPT] or AST [SGOT] >2.5 times the ) or renal impairment (serum creatinine >2 mg/dL)
  • Any evidence of or treatment of (other than localized basal cell, squamous cell skin cancer or cancer in situ that has been resected) within the previous year
  • Any surgery on the stomach, small intestine or colon, excluding appendectomy and cholecystectomy (unless within 60 days of screening visit)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
593 participants (actual)

Study arms

  • Experimental
    50mg BID

    Tenapanor, 50mg BID (100mg total)

    Drug: Tenapanor

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • Also known as: RDX5791, AZD1722

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Overall Response for 6 Out of 12 Weeks

    An overall responder is defined as a weekly responder for the first 6/12 weeks where both CSBM and abdominal pain response criteria were met for the week. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?" The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

    Time frame: First 12 weeks

Secondary outcomes

  1. Percentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 6 Out of 12 Weeks

    An overall CSBM responder is defined as a weekly responder for the first 6/12 weeks. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?"

    Time frame: First 12 weeks

  2. Percentage of Subjects With Overall Abdominal Pain Response for 6 Out of 12 Weeks

    An overall abdominal pain responder is defined as a weekly responder for the first 6/12 weeks. The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

    Time frame: First 12 weeks

  3. Percentage of Subjects With Overall Response for 13 Out of 26 Weeks

    An overall responder is defined as a weekly responder for the first 13/26 weeks where both CSBM and abdominal pain response criteria were met for the week. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?" The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

    Time frame: 26 weeks

  4. Percentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 13 Out of 26 Weeks

    An overall CSBM responder is defined as a weekly responder for the first 13/26 weeks. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?"

    Time frame: 26 weeks

  5. Percentage of Subjects With Overall Abdominal Pain Response for 13 Out of 26 Weeks

    An overall abdominal pain responder is defined as a weekly responder for the first 13/26 weeks. The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

    Time frame: 26 weeks

  6. Percentage of Subjects With Overall Response for 9 Out of 12 Weeks

    An overall responder is defined as a weekly responder for the first 9/12 weeks where both CSBM and abdominal pain response criteria were met for the week. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline and a minimum of at least 3 CSBMs that same week. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?" The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

    Time frame: First 12 weeks

  7. Percentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 9 Out of 12 Weeks

    An overall CSBM responder is defined as a weekly responder for the first 9/12 weeks. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline and a minimum of at least 3 CSBMs that same week. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?"

    Time frame: First 12 weeks

  8. Percentage of Subjects With Overall Abdominal Pain Response for 9 Out of 12 Weeks

    An overall abdominal pain responder is defined as a weekly responder for the first 9/12 weeks. The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

    Time frame: First 12 weeks

07

Results

Posted Apr 13, 2020

Participant flow

Participant flow — Overall Study
Milestone50mg BIDPlacebo
Started293300
Completed219235
Not completed7465

Outcome measures

PrimaryPercentage of Subjects With Overall Response for 6 Out of 12 Weeks

An overall responder is defined as a weekly responder for the first 6/12 weeks where both CSBM and abdominal pain response criteria were met for the week. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?" The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

Time frame:
First 12 weeks
Reported as:
Count of participants · Participants
Percentage of Subjects With Overall Response for 6 Out of 12 Weeks
Participants50mg BIDPlacebo
Percentage of Subjects With Overall Response for 6 Out of 12 Weeks10771
Statistical analysis
  • 50mg BID vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 12.85
SecondaryPercentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 6 Out of 12 Weeks

An overall CSBM responder is defined as a weekly responder for the first 6/12 weeks. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?"

Time frame:
First 12 weeks
Reported as:
Count of participants · Participants
Percentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 6 Out of 12 Weeks
Participants50mg BIDPlacebo
Percentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 6 Out of 12 Weeks139100
Statistical analysis
  • 50mg BID vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 14.11
SecondaryPercentage of Subjects With Overall Abdominal Pain Response for 6 Out of 12 Weeks

An overall abdominal pain responder is defined as a weekly responder for the first 6/12 weeks. The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

Time frame:
First 12 weeks
Reported as:
Count of participants · Participants
Percentage of Subjects With Overall Abdominal Pain Response for 6 Out of 12 Weeks
Participants50mg BIDPlacebo
Percentage of Subjects With Overall Abdominal Pain Response for 6 Out of 12 Weeks146115
Statistical analysis
  • 50mg BID vs Placebo · Cochran-Mantel-Haenszel · p = 0.004 · Risk difference (rd): 11.5
SecondaryPercentage of Subjects With Overall Response for 13 Out of 26 Weeks

An overall responder is defined as a weekly responder for the first 13/26 weeks where both CSBM and abdominal pain response criteria were met for the week. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?" The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

Time frame:
26 weeks
Reported as:
Count of participants · Participants
Percentage of Subjects With Overall Response for 13 Out of 26 Weeks
Participants50mg BIDPlacebo
Percentage of Subjects With Overall Response for 13 Out of 26 Weeks10473
Statistical analysis
  • 50mg BID vs Placebo · Cochran-Mantel-Haenszel · p = 0.003 · Risk difference (rd): 11.16
SecondaryPercentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 13 Out of 26 Weeks

An overall CSBM responder is defined as a weekly responder for the first 13/26 weeks. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?"

Time frame:
26 weeks
Reported as:
Count of participants · Participants
Percentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 13 Out of 26 Weeks
Participants50mg BIDPlacebo
Percentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 13 Out of 26 Weeks12193
Statistical analysis
  • 50mg BID vs Placebo · Cochran-Mantel-Haenszel · p = 0.01 · Risk difference (rd): 10.3
SecondaryPercentage of Subjects With Overall Abdominal Pain Response for 13 Out of 26 Weeks

An overall abdominal pain responder is defined as a weekly responder for the first 13/26 weeks. The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

Time frame:
26 weeks
Reported as:
Count of participants · Participants
Percentage of Subjects With Overall Abdominal Pain Response for 13 Out of 26 Weeks
Participants50mg BIDPlacebo
Percentage of Subjects With Overall Abdominal Pain Response for 13 Out of 26 Weeks147120
Statistical analysis
  • 50mg BID vs Placebo · Cochran-Mantel-Haenszel · p = 0.013 · Risk difference (rd): 10.17
SecondaryPercentage of Subjects With Overall Response for 9 Out of 12 Weeks

An overall responder is defined as a weekly responder for the first 9/12 weeks where both CSBM and abdominal pain response criteria were met for the week. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline and a minimum of at least 3 CSBMs that same week. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?" The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

Time frame:
First 12 weeks
Reported as:
Count of participants · Participants
Percentage of Subjects With Overall Response for 9 Out of 12 Weeks
Participants50mg BIDPlacebo
Percentage of Subjects With Overall Response for 9 Out of 12 Weeks5416
Statistical analysis
  • 50mg BID vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 13.1
SecondaryPercentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 9 Out of 12 Weeks

An overall CSBM responder is defined as a weekly responder for the first 9/12 weeks. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline and a minimum of at least 3 CSBMs that same week. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?"

Time frame:
First 12 weeks
Reported as:
Count of participants · Participants
Percentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 9 Out of 12 Weeks
Participants50mg BIDPlacebo
Percentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 9 Out of 12 Weeks6518
Statistical analysis
  • 50mg BID vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 16.18
SecondaryPercentage of Subjects With Overall Abdominal Pain Response for 9 Out of 12 Weeks

An overall abdominal pain responder is defined as a weekly responder for the first 9/12 weeks. The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

Time frame:
First 12 weeks
Reported as:
Count of participants · Participants
Percentage of Subjects With Overall Abdominal Pain Response for 9 Out of 12 Weeks
Participants50mg BIDPlacebo
Percentage of Subjects With Overall Abdominal Pain Response for 9 Out of 12 Weeks10580
Statistical analysis
  • 50mg BID vs Placebo · Cochran-Mantel-Haenszel · p = 0.015 · Risk difference (rd): 9.17

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
50mg BID0/293 (0%)4/293 (1.4%)47/293 (16%)
Placebo0/300 (0%)8/300 (2.7%)11/300 (3.7%)
Most frequent serious events
Most frequent serious events
Event50mg BIDPlacebo
Abdominal PainGastrointestinal disorders1/2930/300
COPDRespiratory, thoracic and mediastinal disorders1/2931/300
DiarrheaGastrointestinal disorders1/2930/300
NauseaGastrointestinal disorders1/2931/300
Bacterial InfectionInfections and infestations0/2931/300
carotid artery occlusionCardiac disorders0/2931/300
ovarian vein thrombosisVascular disorders0/2931/300
pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2931/300
pyelonephritisRenal and urinary disorders0/2931/300
systemic inflammatory response syndromeImmune system disorders0/2931/300
Most frequent other events
Most frequent other events
Event50mg BIDPlacebo
DiarrheaGastrointestinal disorders47/29311/300

Baseline characteristics

Age, Continuous
Age, Continuous(years)50mg BIDPlaceboTotal
Mean46.1 ± 13.144.8 ± 13.845.4 ± 13.46
Sex: Female, Male
Sex: Female, Male(Participants)50mg BIDPlaceboTotal
Female240247487
Male5353106
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)50mg BIDPlaceboTotal
Hispanic or Latino7778155
Not Hispanic or Latino216222438
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)50mg BIDPlaceboTotal
American Indian or Alaska Native101
Asian12921
Native Hawaiian or Other Pacific Islander000
Black or African American9292184
White185192377
More than one race134
Unknown or Not Reported246
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)50mg BIDPlaceboTotal
Mean30.50 ± 7.1830.88 ± 7.2730.69 ± 7.22
08

Study locations

117 sites
  • Ardelyx Investigative Site 257
    Dothan, Alabama 36305, United States
  • Ardelyx Investigative Site 200
    Foley, Alabama 36535, United States
  • Ardelyx Investigative Site 103
    Huntsville, Alabama 35801, United States
  • Ardelyx Investigative Site 244
    Huntsville, Alabama 35801, United States
  • Ardelyx Investigative Site 251
    Huntsville, Alabama 35801, United States
  • Ardelyx Investigative Site 100
    Huntsville, Alabama 35802, United States
  • Ardelyx Investigative Site 209
    Saraland, Alabama 36571, United States
  • Ardelyx Investigative Site 210
    Phoenix, Arizona 85018, United States
  • Ardelyx Investigative Site 296
    Phoenix, Arizona 85018, United States
  • Ardelyx Investigative Site 269
    Tucson, Arizona 85704, United States
  • Ardelyx Investigative Site 256
    Tucson, Arizona 85710, United States
  • Ardelyx Investigative Site 292
    Conway, Arkansas 72034, United States
  • Ardelyx Investigative Site 122
    Little Rock, Arkansas 72212, United States
  • Ardelyx Investigative Site 163
    Anaheim, California 92801, United States
  • Ardelyx Investigative Site 105
    Canoga Park, California 91303, United States
  • Ardelyx Investigative Site 143
    Chula Vista, California 91910, United States
  • Ardelyx Investigative Site 147
    Encino, California 91436, United States
  • Ardelyx Investigative Site 297
    La Mesa, California 91942, United States
  • Ardelyx Investigative Site 284
    La Mirada, California 90638, United States
  • Ardelyx Investigative Site 107
    Lomita, California 90717, United States
  • Ardelyx Investigative Site 165
    Long Beach, California 90807, United States
  • Ardelyx Investigative Site 211
    Orange, California 92868, United States
  • Ardelyx Investigative Site 233
    Wheat Ridge, Colorado 80033, United States
  • Ardelyx Investigative Site 212
    Bristol, Connecticut 06010, United States
  • Ardelyx Investigative Site 176
    Brandon, Florida 33511, United States
  • Ardelyx Investigative Site 178
    Cutler Bay, Florida 33157, United States
  • Ardelyx Investigative Site 136
    Hialeah, Florida 33012, United States
  • Ardelyx Investigative Site 130
    Hialeah, Florida 33016, United States
  • Ardelyx Investigative Site 191
    Lynn Haven, Florida 32444, United States
  • Ardelyx Investigative Site 127
    Miami Lakes, Florida 33014, United States
  • Ardelyx Investigative Site 288
    Miami, Florida 33144, United States
  • Ardelyx Investigative Site 106
    Miami, Florida 33186, United States
  • Ardelyx Investigative Site 179
    Orlando, Florida 32803, United States
  • Ardelyx Investigative Site 290
    Tampa, Florida 33607, United States
  • Ardelyx Investigative Site 254
    West Palm Beach, Florida 33409, United States
  • Ardelyx Investigative Site 138
    Atlanta, Georgia 30312, United States
  • Ardelyx Investigative Site 148
    Atlanta, Georgia 30342, United States
  • Ardelyx Investigative Site 253
    Atlanta, Georgia 30342, United States
  • Ardelyx Investigative Site 272
    Decatur, Georgia 30032, United States
  • Ardelyx Investigative Site 229
    Decatur, Georgia 30033, United States
  • Ardelyx Investigative Site 250
    Marietta, Georgia 30060, United States
  • Ardelyx Investigative Site 137
    Norcross, Georgia 30071, United States
  • Ardelyx Investigative Site 213
    Savannah, Georgia 31406, United States
  • Ardelyx Investigative Site 124
    Snellville, Georgia 30078, United States
  • Ardelyx Investigative Site 268
    Burr Ridge, Illinois 60527, United States
  • Ardelyx Investigative Site 227
    Evergreen Park, Illinois 60805, United States
  • Ardelyx Investigative Site 291
    Hoffman Estates, Illinois 60169, United States
  • Ardelyx Investigative Site 202
    Oak Lawn, Illinois 60453, United States
  • Ardelyx Investigative Site 218
    Evansville, Indiana 47714, United States
  • Ardelyx Investigative Site 158
    Madisonville, Kentucky 42431, United States
  • Ardelyx Investigative Site 270
    Mandeville, Louisiana 70471, United States
  • Ardelyx Investigative Site 214
    Marrero, Louisiana 70072, United States
  • Ardelyx Investigative Site 154
    Metairie, Louisiana 70006, United States
  • Ardelyx Investigative Site 195
    Shreveport, Louisiana 71103, United States
  • Ardelyx Investigative Site 271
    Bangor, Maine 04401, United States
  • Ardelyx Investigative Site 160
    Annapolis, Maryland 21401, United States
  • Ardelyx Investigative Site 255
    Towson, Maryland 21204, United States
  • Ardelyx Investigative Site 267
    Brockton, Massachusetts 02302, United States
  • Ardelyx Investigative Site 260
    Ann Arbor, Michigan 48106, United States
  • Ardelyx Investigative Site 283
    Buckley, Michigan 49620, United States
  • Ardelyx Investigative Site 239
    Flint, Michigan 48504, United States
  • Ardelyx Investigative Site 168
    Troy, Michigan 48098, United States
  • Ardelyx Investigative Site 216
    Wyoming, Michigan 49519, United States
  • Ardelyx Investigative Site 221
    Biloxi, Mississippi 39531, United States
  • Ardelyx Investigative Site 282
    Jefferson City, Missouri 65109, United States
  • Ardelyx Investigative Site 228
    Saint Louis, Missouri 63042, United States
  • Ardelyx Investigative Site 156
    Billings, Montana 59102, United States
  • Ardelyx Investigative Site 182
    Las Vegas, Nevada 89128, United States
  • Ardelyx Investigative Site 175
    Vineland, New Jersey 08360, United States
  • Ardelyx Investigative Site 222
    Albuquerque, New Mexico 87102, United States
  • Ardelyx Investigative Site 264
    Albuquerque, New Mexico 87106, United States
  • Ardelyx Investigative Site 230
    Brooklyn, New York 11206, United States
  • Ardelyx Investigative Site 170
    Great Neck, New York 11023, United States
  • Ardelyx Investigative Site 203
    New Hyde Park, New York 11040, United States
  • Ardelyx Investigative Site 205
    Fayetteville, North Carolina 28304, United States
  • Ardelyx Investigative Site 190
    Greensboro, North Carolina 27408, United States
  • Ardelyx Investigative Site 194
    Hickory, North Carolina 28601, United States
  • Ardelyx Investigative Site 285
    Wilmington, North Carolina 28401, United States
  • Ardelyx Investigative Site 172
    Beavercreek, Ohio 45432, United States
  • Ardelyx Investigative Site 204
    Cincinnati, Ohio 45212, United States
  • Ardelyx Investigative Site 201
    Cincinnati, Ohio 45234, United States
  • Ardelyx Investigative Site 173
    Dayton, Ohio 45429, United States
  • Ardelyx Investigative Site 208
    Franklin, Ohio 45005, United States
  • Ardelyx Investigative Site 171
    Huber Heights, Ohio 45424, United States
  • Ardelyx Investigative Site 219
    Lima, Ohio 45806, United States
  • Ardelyx Investigative Site 232
    Wadsworth, Ohio 44281, United States
  • Ardelyx Investigative Site 236
    Oklahoma City, Oklahoma 73103, United States
  • Ardelyx Investigative Site 273
    Tulsa, Oklahoma 74135, United States
  • Ardelyx Investigative Site 220
    Levittown, Pennsylvania 19056, United States
  • Ardelyx Investigative Site 248
    East Providence, Rhode Island 02914, United States
  • Ardelyx Investigative Site 252
    Columbia, South Carolina 29204, United States
  • Ardelyx Investigative Site 265
    Gaffney, South Carolina 29341, United States
  • Ardelyx Investigative Site 246
    Rapid City, South Dakota 57702, United States
  • Ardelyx Investigative Site 261
    Sioux Falls, South Dakota 57108, United States
  • Ardelyx Investigative Site 217
    Chattanooga, Tennessee 37404, United States
  • Ardelyx Investigative Site 121
    Franklin, Tennessee 37064, United States
  • Ardelyx Investigative Site 189
    Hermitage, Tennessee 37076, United States
  • Ardelyx Investigative Site 133
    Jackson, Tennessee 38305, United States
  • Ardelyx Investigative Site 109
    Knoxville, Tennessee 37909, United States
  • Ardelyx Investigative Site 266
    Memphis, Tennessee 38119, United States

Showing the first 100 of 117 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Chey WD, Lembo AJ, Yang Y, Rosenbaum DP. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2). Am J Gastroenterol. 2021 Jun 1;116(6):1294-1303. doi: 10.14309/ajg.0000000000001056. PubMed 33337659 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Aug 2017 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2020, 2 years 8 months after primary completion. A results delay was requested in Mar 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2016
First posted
Feb 19, 2016
Start
Dec 2015
Primary completionActual
Aug 2017
CompletionActual
Oct 2017
Results delay requested
Mar 11, 2019
Results first posted
Apr 13, 2020
Last update
Apr 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02686138
Lead sponsor
Ardelyx
Responsible party
Sponsor
First posted
Feb 19, 2016
Start date
Dec 2015
Primary completion
Aug 2017
Completion
Oct 2017
Results posted
Apr 13, 2020
Last update
Apr 22, 2020

Study contacts

David P Rosenbaum, Ph.D.
study chair · Ardelyx, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenapanor

Start the discussion